Mechanisms of Genome-Wide Association and Disease Risk
The majority of non-Mendelian disease-associated variation resides outside of structural genes, and is presumed to regulate gene expression rather than encoded protein structure [4, 5, 6•, 7] . Thus far, single nucleotide polymorphisms (SNPs) appear to be the type of variation that contribute the majority of known genetic risk, and relatively few studies have identified the causal variants and mechanisms for the expanding number of disease associations. In these cases, the causal SNP has been shown to alter: i) transcription factor (TF) binding and causal gene transcription [8-10, 11••, 12-15, 16••, 17] , ii) post-transcriptional gene expression as mediated by regulatory miRNA [18, 19] , iii) genomic methylation patterns that regulate gene expression [20, 21] , and iv) expression of long non-coding RNAs that likely regulate expression of the causal gene [22••] . Importantly, each of the first three mechanisms is expected to result in allele-specific expression of the causal gene, as well as lncRNAs if its effect is in cis [23] .
Studies to date suggest that disruption of transcription factor and miRNA binding sites are the most common functional mechanisms for causal variation-mediated regulation of gene expression [24] . To determine the relative contribution of each of these mechanisms to CHD, we estimated the number of GWAS CHD-associated and correlated SNPs in both EN-CODE chromatin immunoprecipitation sequencing (ChIPseq) TF binding regions (~4,400,000) and miRcode predicted miRNA binding sites (~1,100,000). We identified 3520 total variants, including CHD-associated variants and those in high LD (r 2 >0.8). Of these, 676 (19.2 %) were found to reside in a TF binding region (of which 62 reside directly in a highly conserved TFBS), and 36 (1 %) were found to reside in a miRNA binding site (either moderately or highly conserved).
While such analyses have limitations, they strongly suggest that disruption of TF binding is much more common than disruption of miRNA binding. Therefore, studies concentrating on transcriptional regulatory mechanisms that likely contribute the majority of disease risk would be expected to provide more immediate insight into upstream epigenetic pathways ( Table 1) .
Identification of Causal Variation

Extending Human Genetic Association Data
Given the whole-genome association data, there are a number of computational and follow-up genetic analyses that will provide critical insight into which of a number of associated SNPs represent the causal variation. First, it is possible to use available algorithms to increase the number of SNPs for which association data can be generated. In this process, termed "imputation," available genotyping data is extended to non-genotyped SNPs through computational analysis from the genotypes at SNPs for which assays were available, and can provide coverage up to several million SNPs in the genome [25] . Such studies can point to a causal SNP that was not genotyped on the original array or can point to additional associated SNPs that must be considered in the list of possible causal variants. Other purely computational approaches include conditional analyses that allow the association signal at individual associated SNPs to be removed and the relative signal at other SNPs to be quantified [2••] .
Follow-up genetic studies include resequencing and finemapping with targeted genotyping assays in specific loci in a number of cases to identify common and rare variation that might drive the association. For example, a meta-analysis was conducted by the CARDIoGRAM + C4D consortium with GWAS fine-mapping chip (Metabochip) data that contained dense SNP sets in loci associated with cardiovascular, metabolic, and other traits, and these studies identified a number of alleles that were not identified in the initial meta-analysis
. Independent novel alleles were identified in the 9p21.3, COL4A2, CXCL12, and TCF21 loci with this approach. Also, follow-up association studies in racial-ethnic groups other than those used in the initial analysis may more directly point to causal variation due to local differences in linkage disequilibrium [26] . Studies in African-American cohorts have provided evidence of a second allele in the 9p21.3 locus [27••] , and studies in Han Chinese have identified a second allele in the TCF21 locus [28•] . These findings have added significantly to the certainty of the association in Caucasians and have provided additional avenues of study for investigating the mechanisms of association.
Use of Genomic Data Characterizing Chromosomal Structure
As noted above, there is mounting evidence that altered transcription factor binding is a common mechanism by which causal allelic variation mediates CHD risk. Through ongoing efforts by the ENCODE consortium and the NIH Roadmap Reference Epigenome consortia, genome-wide chromatin organization has been assessed in distinct cultured cells using DNase-seq and FAIRE-seq approaches. Additionally, genome-wide post-translational histone modifications that reflect transcriptional activity or repression have been mapped for a number of cultured cell types. Drs. Greenleaf and Chang at Stanford recently developed a new method to map chromatin accessibility using transposon integration and highthroughput sequencing (ATAC-seq) that promises to provide higher resolution with fewer starting cells [29] . The value of these data is in highlighting regions of the genome that are likely to mediate transcription and serve as sites of functional regulatory variation associated with CHD. Several groups have developed statistical and analytical methods to incorporate such data into an analytical paradigm aimed at identifying causal variants [30] . Our group has mapped chromatin organization in human coronary artery smooth muscle cells (HCASMC) and has used these data to help identify causal variation for two of the disease-associated alleles at TCF21 [31••] . Finally, it is important to note that scanning genomic sequences for altered miRNA binding sites, often by 3'-UTR variants, may represent another level of gene regulation associated with disease risk, as demonstrated for many cancers [32, 33] . We have recently identified TCF21 as the first CHDassociated gene to be regulated by a miRNA that is disrupted by disease associated variation [34] .
Genetics of Gene Expression
Considerable effort has been focused on defining the links between common polymorphisms in the genome and target gene expression levels through which causal variation can be identified. By combining whole-genome expression profiling by either microarray or RNAseq studies with whole-genome genotyping, it has been possible to identify allelic variation that correlates with gene expression [35, 36•] . Such expression quantitative trait loci (eQTLs) can be mapped in close proximity (cis-eQTL) or at considerable distance (transeQTL) from the gene of interest. cis-eQTLs often identify TFBS that mediate local control of gene expression, while trans-eQTLs identify transcription factors that regulate expression of genes that reside in the locus of interest. ciseQTLs have been shown to be highly enriched in those SNPs most closely associated with complex human traits and diseases, and often represent causal variation [37, 38] . eQTL datasets have been generated for a number of human tissues, including brain, circulating leukocytes, adipose, and liver tissues, and these datasets are now widely available [39] .
cis-eQTLs in linkage disequilibrium (LD) with diseaseassociated SNPs are also good candidates for identifying + Provides robust knowledge-based enrichment of genes and pathways from large-scale genomic or proteomic approaches [100] -Potential biases due to curation of select pathways and phenotypes causal variation, but there are significant limitations with these data. It is important to realize that numerous SNPs in a region of the genome may score as eQTLs due to linkage disequilibrium, with no clear indication of which SNP is driving the effect. It is also likely that phenotypic associations reflect eQTLs driven by specific tissue/cell contexts, and thus examining tissues/cells irrelevant to the disease may miss critical eQTL effects. Ongoing efforts such as the NIH GenotypeTissue Expression (GTEx) initiative are developing eQTL datasets that may be highly useful for mapping regulatory variation in a broader range of human tissues (http://www. ncbi.nlm.nih.gov/gtex/GTEX2/gtex.cgi).
A second approach employing genetics of gene expression data compares relative mRNA levels for the two alleles of the candidate causal gene in informative heterozygous individuals, and thus measures allele-specific expression (ASE). As both alleles are exposed to the same environmental and transgenetic factors, as well as to the same technical biases when sequencing, relative abundance of allele-specific transcripts can reflect cis-acting effects. Correlation of the ASE with genotype has been employed to identify multiple types of mechanisms related to a variety of human diseases [40] [41] [42] [43] [44] and to map causal variation for a number of disease phenotypes [11••, 40, 45-47] . Functional genomic assays and statistical methods have been developed that utilize ASE data to connect trait-associated variants to genes and support mapping of cis-acting causal regulatory variation. RNA-seq is increasingly employed to provide better assessment of gene expression for such studies, although these approaches are limited in that ASE information from RNA-seq can be biased due to differences in sampling depths driven by differences in expression level across genes [48] . To address this, the Montgomery and Li labs have recently developed a targeted ASE sequencing method using microfluidics-based multiplex PCR and sequencing (mmPCR-seq) [49] . This system allows one to target and sequence the RNA of as many as 1000 heterozygous positions and to assess allelic imbalance with high fidelity. By further multiplexing samples, this approach provides an efficient and low-cost solution for assessing the impact and extent of ASE in a population sample.
Identification of Causal Genes
Obviously, identification of the causal gene is critical for studies investigating the cellular mechanism of that gene in experimental model systems. In many cases, the causal gene in loci identified through GWAS investigation is the one closest to the genome-wide variation [38] This is not always true, however, and in some cases there are multiple proximally spaced protein-coding genes in the region of the associated SNPs, requiring additional analysis to discriminate between the candidate genes. To date, genetics of gene expression data have provided the best approach for identifying causal genes at GWAS loci. For instance, eQTL information has commonly been incorporated into the CARDIoGRAM and CARDIo-GRAM+C4D meta-analyses to better identify the genes that mediate the risk association [1••, 2••]. Use of allele-specific gene expression data has been used to identify those genes in the region of association that are in disequilibrium and thus likely to be under the influence of causal variation in the associated loci.
In the context of CHD GWAS loci, challenges associated with causal variant and gene identification at 9p21.3 have significantly impeded progress toward understanding the disease mechanisms associated with this important locus and highlight the limitations/challenges of gene regulatory-based methods in general. CHD associations at 9p21.3 were characterized by the identification of an approximately 50-kb block of highly correlated SNPs (chromosome 9 coronary arteryassociated region, C9CAR), and these variants were over 50 kb from the nearest protein-coding genes, a pair of cyclin-dependent kinase inhibitor (CDKI) genes [50••, 51••, 52]. Interestingly, the CDKI genes were found to be connected by an antisense long non-coding RNA (CDKN2B-AS1 or ANRIL) transcribed on the opposite strand to the nearest CDKI gene, CDKN2B [53] . A number of eQTL and ASE studies have been conducted, with considerably varied results [54] . Holdt et al. found increased expression of the large C9CAR lncRNA, ANRIL, in peripheral blood mononuclear cells from 1134 CHD patients with the 9p21 risk allele, but found no change in expression of nearby genes of CDKN2A, CDKN2B, or ARF [55•]. By contrast, Liu et al. found significantly reduced expression of CDKN2A, CDKN2B, ARF, and CDKN2B-AS1 in peripheral blood T-cells from 170 healthy individuals with the risk allele [56] . Further, in whole-blood studies of 124 subjects, Jarinova et al. found that RNA expression of the short variants of ANRIL was increased 2.2-fold, whereas expression of the long ANRIL variant was decreased 1.2-fold, in healthy subjects homozygous for the risk allele [57] . Expression levels of the long ANRIL variant (CDKN2B-AS1) were positively correlated with that of CDKN2B, while short variants were inversely correlated. In general, however, most studies suggested that CDKN2B-AS1 and CDKN2B expression are inversely correlated.
The differing results from the various eQTL studies were almost certainly due to inadequate sample size, the use of nondiseased tissues, or the use of complex tissues that included multiple non-disease-related cell types. Detailed studies by Cunnington et al. with peripheral blood samples showed a low-level positive correlation between CDKN2A, CDKN2B, and CDKN2B-AS1 mRNA levels. More importantly, however, with elegant ASE studies they showed that ANRIL was the gene most highly correlated with genotype at C9CAR and that individual SNPs had an inverse effect on CDKN2B and CDKN2B-AS1 expression [58] . From a mechanistic point of view, inverse correlation of these genes was consistent with experiments showing that transcription initiated from the ANRIL promoter suppresses transcription of CDKN2B [59] , as well as studies showing that ANRIL recruits polycomb complex proteins that suppress expression of CDKN2B [60] . As noted previously, studies in African American cohorts and recent large-scale fine-mapping studies in Caucasians and South Asians have identified an independent SNP in the CDKN2B gene that is not in LD with those at C9CAR, thus implicating this gene as causal. Of course, the 9p21 locus has also been the subject of other approaches to identify the causal gene, including those by Harismendy et al., who used chromosome conformation capture and other methods to identify a gamma interferon-responsive gene in this locus [61] , as well as CDKI gene deletion studies coupled with mouse genetic models and mechanistic in vitro studies [62, 63] .
Experimental Methods to Study Transcriptional Mechanisms of Disease Association
Identification of Transcription Factor Binding Motif and Consensus Binding Proteins As described previously, the majority of disease-associated variation likely resides outside of structural genes to regulate gene expression [4, 5, 24] , and causal variants are increasingly found to be eQTLs [37] . Therefore, a further understanding of upstream pathways and specific disease mechanisms requires the study of transcriptional pathways that regulate expression of the causal gene and are disrupted by causal variation. Such studies have been validated for a number of disease-associated variants [9, 10, 11••, 12-15, 17] . It is also possible that regulatory elements may be created by causal variation that introduces a TFBS, and thus aberrant activation of the causal gene, producing a maladaptive phenotype. Scanning the genomic sequence surrounding putative causal variants using in silico prediction tools may also reveal cooperative TFBS or the functional identity of TF complexes. Searching relevant gene co-expression datasets may also identify specific TF family members that are predicted to interact with the binding site.
There are two highly cited databases, TRANSFAC [64] and JASPAR [65] , that archive and organize knowledge of DNA binding TFs, TFBSs, and their regulated genes. TRAN SFAC and JASPAR are accessible databases of transcription factor binding models and can be used to identify putative DNA binding sites in a queried DNA sequence. Affinity in the context of TF binding is represented with a position weight matrix (PWM) or a position-specific scoring matrix (PSSM). These models can be used to scan a genome for putative TF binding sites that have high similarity to the model. Other PWM-or PSSM-based databases include MatInspector [66] and UniPROBE [67] , which rely on protein-binding microarray datasets, and databases like ORegAnno [68] and PAZAR [69] , which have attempted to collect and curate individual experimentally proven transcription factor binding sites from the literature and datasets from ChIP-seq and other genomewide experiments. In addition, this research direction has been significantly supported by recent high-throughput methods, including the use of systematic evolution of ligands by exponential enrichment (SELEX) and next-generation sequencing to define the binding profiles for 800 transcription factors [70] .
In the simplest paradigm, with at least one of the database searches, the causal variant region will provide a clear contrast between alleles, with one allele having a score >90 and the other having a score of <80 (see analyses in Miller et al.) [31••] . In most cases, the protective allele is expected to have the higher score, although it is possible that the risk allele score will be higher. The two alleles may also show predicted preferences for different members of the same family, with both alleles showing a high score but to different family members or structurally related TFs. In some cases, the search algorithms return family names (e.g., AP-1), and at other times will predict binding of specific factors (e.g., ATF2) in cases where there may be minor differences in binding sequences among the family members.
Identification of candidate transcriptional networks that are associated with causal CHD variants and genes provides valuable information regarding upstream signaling pathways that regulate activation of these TFs and thus mediate disease risk. For instance, studies in this laboratory have identified embryonic and growth factor signaling pathways that may mediate a portion of the disease risk at the TCF21 locus. Platelet-derived growth factor (PDGF)-dependent AP-1 factors (c-Jun, JunD, and ATF3) were shown to preferentially bind and trans-activate an enhancer element containing the risk allele at rs12190287 [31••] . However, binding of the epicardial developmental factor Wilms' tumor (WT1) to the risk allele led to trans-repression of this element [31••] . The complex architecture of transcription factor binding complexes containing both activators and repressors thus requires robust experimental validation to elucidate causal mechanisms of in silico predicted TF binding to disease-associated variants.
In Vitro Studies of Transcription Factor Binding to Causal Regulatory Motifs
Many families of transcriptional regulatory factors have now been identified, their binding sequences defined, and their association with basic aspects of cell-specific hormonal and biophysical gene regulation investigated [65, 71] . In addition, many TFs have been studied in the context of upstream signaling pathways that modulate their function, and identification of the TF often points to fundamental growth factor or cytokine signaling pathways that modulate cellular functions. TF binding sequences have historically been investigated with in vitro DNase I footprinting and gel mobility shift assays, but these techniques have now given way to chromatin immunoprecipitation (ChIP) that better reflects the in vivo state of chromatin in the region under study. For this approach, cultured cells or tissues are fixed in the native state, providing crosslinking of TFs to DNA and, when coupled with immunoprecipitation with specific TF antibodies, providing assessment of binding to DNA regions of interest. Antibodies are now available for a large number of the protein factors that mediate transcriptional regulation, and a number of vendors have validated their antibodies to TFs specifically for the ChIP procedure.
If differences in TF binding in the CHD locus and resulting overall differences in transcription level is the mechanism by which causal variants mediate disease risk, it is predicted that TF binding to the risk versus protective allele in vivo is different. This can be assessed by performing ChIP and quantifying the relative amount of DNA representing each allele that is immunoprecipitated from vascular cells that are heterozygous for the causal SNP (HaploChIP) [72••] . Allele-specific quantitation of binding is assessed by employing genotyping primers in a qPCR reaction or other methodology that quantifies the number of DNA molecules for each allele. We have employed this approach in recent studies of CHD risk association at the 6q23.2 region, primarily using qPCR with genotyping primers and using pyrosequencing as a second confirmatory method [31••] .
If there are allele-specific differences in TF binding in the causal variant region, it is also expected that this will correlate with differences in local chromatin architecture. To investigate this possibility, well-validated histone modification antibodies are employed to verify that the allele with greater TF binding shows a more open configuration, as evidenced by increased amplification of that allele (HistoneMod-ChIP). We have recently used this approach in studies of chromatin configuration at rs12190287 in the CHD-associated region at 6q23.2 [31••] . Identification of specific TFs will point to upstream signaling pathways and epigenetic mechanisms that could be further investigated in the context of overall gene expression for the CHD-associated genes [31••] .
Reporter Gene Studies
It is essential to follow up the previously described TFBS prediction and ChIP studies with reporter gene transfection experiments investigating the ability of the causal regulatory variants to alter expression in an allele-specific fashion. These studies address the critical issue of directionality of predicted TF binding factors and whether there is a difference in transcriptional activity between the two alleles when the TFBS is accessible for binding. It is also important to verify that transcriptional activity is appropriately modified when cells are grown in the presence or absence of upstream pathway activation. The direction of effect seen with the reporter assays is important and, when combined with the direction of effect observed in the GWAS studies, provides valuable information regarding the upstream signaling pathways. Lastly, by incorporating loss-of-function studies (using siRNAs against upstream TFs) with the reporter assays, it is possible to confirm the identification and function of the specific TFs implicated by the ChIP experiments. This is important, as some antibodies detect more than one TF family member, and evidence of TF binding does not imply activation.
The recent development of high-throughput methods affords new opportunities for the study of putative TFBS identified through GWAS and follow-up studies. One is able to simultaneously investigate all of the associated loci and those in high LD to look for those putative TFBS identified by disease-related SNPs. Massively parallel reporter assays have been used to simultaneously interrogate over 2000 putative enhancers in vitro, and STARR-seq and CRE-seq methods have been developed for the purpose of querying a large number of putative enhancer regions related to GWAS loci [73] [74] [75] .
It is anticipated that luciferase assay results from these reporter gene transfection studies will track with TF binding, with the two alleles showing different transcriptional activity, and with contextual dependence of protein binding expected to be mirrored in transcriptional activity and specificity. In most cases, identification of specific TFs through changes in transcriptional activity in association with siRNA inclusion in the reporter gene transfections is expected to be congruent with findings in ChIP experiments. Verification of a transcription regulatory sequence with allelic functional differences, along with identification of the cognate regulatory protein, will point to growth factor, cytokine, or other regulatory pathways that signal to the CHD locus and which thus warrant further study.
Evaluation of Enhancer Function at Modified TFBS
Previous in vitro studies will establish that when the TFs have access -i.e., in the presence of open chromatin -their function is modulated by the alteration in sequence introduced by the causal SNP. There will be doubt remaining, however, with respect to the ability of the TFBS to function as predicted in the in vivo setting -i.e., whether this site is truly an "enhancer"-like region in vivo. We postulate that the majority of the TFBSs and cognate TFs that are associated with CHD causal variation mediate signaling through fundamental enhancer pathways that are involved with embryonic development, SMC lineage determination, and/or vascular wall-specific functions such as SMC response to injury and contribution to atherosclerotic disease. This hypothesis builds on numerous examples whereby enhancer region function appears to be altered by complex disease-associated allelic variation: for metabolic disease in the TCF7L2 locus [12, 76] , colorectal cancer in the SMAD7 gene at 18q21 [13] and the EIF3H gene at 8p23.3 [14] , and several forms of cancer linked to a SNP in a MYC enhancer region [9, 10, 15] . For a small number of disease-associated causal regulatory variants, transgene expression has validated the in vivo relevance of an associated enhancer in mouse or Xenopus models [13, 15] . To investigate the gene expression patterns that are specific to transcription factor pathways associated with CHD causal variants, we propose the expression of transgenic constructs containing either the risk or protective allele TFBS in the context of mouse embryonic development and response to vascular injury and atherosclerotic disease. These studies would address i) whether the causal regulatory variant resides in a functional enhancer region, and ii) whether the causal regulatory SNP alters the function of this enhancer.
Genome Editing Applications for CHD Loci
Recent advances in site-specific genome editing/targeting technologies have enabled highly efficient targeting of genetic loci in mammalian cells and tissues. It seems likely that these tools will be adopted for the functional interrogation of GWAS loci for complex diseases. First-generation genome editing approaches involved zinc-finger nucleases (ZFN) to produce either double-strand breaks (DSBs) or edited alleles using natural repair mechanisms: homologous recombination (HR) or non-homologous end-joining (NHEJ). More recently, transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPRs)/CRISPR-associated systems (Cas) have been developed. These modern genome editing tools have enabled the modification of genomic sites of interest in both mammalian cells and model organisms. Importantly, when coupled with induced pluripotent stem cell (iPSC)-derived primary human cells, these approaches hold translational potential in investigation of GWAS signals in patient samples from casecontrolled studies for either diagnostic or therapeutic purposes.
ZFNs represent a class of engineered nucleases that create DSBs as heterodimers and can be modified to recognize specific genomic sequences. Essentially, site-specific DNAbinding domains are fused to a FokI-derived nuclease domain to direct DNA cleavage. ZFN-based genome targeting was recently used to introduce disease-causing mutations into the safe harbor gene locus (PPP1R2C/AAVS1) in iPSCs and human embryonic stem cells [77] . Importantly, these ZFNedited iPSC-endothelial cell and cardiomyocytes in mouse lines were tracked over time using multi-modality imaging techniques [77] . ZFNs have been extensively used for targeted gene inactivation in zebrafish models [78, 79] and, more recently, in rats to investigate the function of the hypertension candidate gene ADAMTS16 [80] .
Derived from bacterial plant pathogens, TAL effector proteins have been engineered as the next generation of genome targeting systems. Similar to ZFNs, TALENs are generated by fusing DNA-binding domains to the FokI nuclease domain, and they have highly efficient nuclease activity along with more reliable gene targeting. More recently, bacteria and archaea-derived CRISPR/Cas based genome targeting systems have further revolutionized RNA-guided genome engineering, with even greater targeting efficiency and scalability in multiple model systems. By designing site-specific guide RNAs with a short protospacer adjacent motif (PAM) sequence at the 3' end, complementary genomic target sites can be targeted by the Cas9 nuclease for cleavage. It is now possible to inactivate, repress, or activate multiple genes in both human cells and mouse models with approximately 80 % efficiency [81, 82] . The ease of use of this technology is expected to accelerate the functional interrogation of multiple CHD GWAS loci in iPSC-derived vascular cells from patients harboring multiple disease variants as well as in mouse models of atherosclerosis. Up to five gene regions have been targeted at once [82] , suggesting knockouts of diseaseassociated gene networks or pathways in future studies. For instance, once allele-specific TF complexes have been fully characterized in relevant model systems, these could be inactivated along with the target locus to disrupt CHDassociated regulatory networks. Recent modifications of the Cas9 system to generate nuclease-deficient Cas9 (dCas9) fused to functional regulatory domains such as VP16 (activating) and KRAB (repressing) have enabled the modulation of specific genomic regions [83•] . Potential limitations of these approaches include off-targeting effects that may complicate functional interpretation if mutations are introduced in transcripts within the same disease network. However, recent transcriptome-wide evidence suggests that these off-target mutations are rare events with the use of the CRISPR-based system [82] . Taken together, these tools may be directly applied to define the function of multiple noncoding regulatory variants at GWAS loci.
Identification of Upstream Signaling Pathways
A major challenge in investigating the causal mechanisms of GWAS signals is defining the relevant upstream stimuli converging on regulatory variants. As mentioned above, these pathways could be indirectly inferred from identified TFs at cis-regulatory elements using various pathway analysis tools and databases that can be customized with cell-or genespecific expression datasets (e.g., microarray or RNA-seq) or TF binding datasets (e.g., ChIP-seq Genome-wide or proteome-wide techniques have the potential to elucidate the unanticipated binding of TF complexes and inference of relevant pathways at GWAS loci. As noted previously, ChIP-seq is a powerful high-throughput approach to uncover multiple TFBS in the native chromatin context. When coupled with gene set enrichment tools such as GREAT and PRISM, the upstream pathways can be inferred from experimental evidence and phylogenetic conservation. Recent modifications of ChIP-seq include ChIP-exo, through which exonucleases can be applied to gain single-nucleotide resolution of TF binding [84] . There remain limitations to ChIPbased approaches, however, including the lack of validated antibodies to the majority of the TFs in the human proteome, the requirement of large numbers of cells (especially for lowabundant TFs), and the inability to define dynamic and heterogeneous TF complexes. Signaling pathways are driven by specific ligand or mechanical cues to alter defined spatial and temporal cascades. Further, modulation of TFs to turn on or turn off expression often relies on rapid site-specific posttranslational modifications, such as protein phosphorylation. Complementary approaches to capture this depth of signaling at sites of genetic variation include DNA affinity/pull-down mass spectrometry [85] . Studies have applied allele-specific biotinylated oligo precipitation to capture TF protein-binding complexes to regulatory SNPs, which can be identified from eluate fractions using standard LC-MS mass spectrometry. If applied to cross-linked chromatin samples at distinct cellular states and time points, this approach has the potential to provide a more comprehensive view of functional TF complexes at GWAS loci. Alternatively, RNA immunoprecipitation (RIP) followed by next-generation sequencing [86] or LC-MS mass spectrometry [87] could also reveal RNAdependent interactions at disease variants involving RNA cofactors as well as miRNA and long non-coding RNA (lncRNA).
Perspective
The above approaches are largely restricted to pooled populations of cells, which may not entirely resolve the causal mechanisms and upstream pathways at individual loci. Further refinements may include single-cell analyses of TF binding at sites of regulatory variation using "SMART" RNA-seq or microfluidics [88] . By sequencing transcriptomes of single immune cells, studies have revealed wide temporal heterogeneity in gene expression and splicing patterns. In addition, the integration of multiple-omics datasets of gene expression, chromatin binding, protein-protein interaction, or other functional measures could further define causal regulatory mechanisms at disease loci [89, 90] . Finally, more robust statistical or machine learning tools could be applied to existing methods to accurately infer disease mechanisms [91, 92] . It is anticipated that a combination of both experimental and computational paradigms would be required to prioritize, predict, and target functional mechanisms of the expanding number of CHD associations.
Conclusions
Progress in human genetic whole-genome studies over the past few years has finally provided investigators with loci and genes that are incontrovertibly linked to causal mechanisms in the atherosclerotic vessel wall. While it is early days with respect to the identification of molecular and cellular causal effects that underlie disease initiation and progression, there are now highly sophisticated tools that allow the identification of causal variation, causal genes, and the signaling pathways upstream and downstream of the disease gene that can be targeted for treatment of the primary disease process.
